
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas is a company with an innovative approach to treat debilitating and life-threatening diseases by targeting specific disease-causing proteins. The company has a strong pipeline with promising product candidates in both oncology and neuroscience, backed by partnerships with large pharmaceutical companies. With the successful completion of the VEPPANU deal, the company is now well-funded and has a clear path to achieving key milestones that could drive significant value for investors. Furthermore, recent positive data from its product ARV-102 in PD patients and upcoming data from its PSP program demonstrate the potential of its protein degradation platform. The company is well-positioned for potential growth and success in the biotech industry.
Bears say
Arvinas is facing potential competition in the protein degradation space with multiple other companies also working on similar technologies and treatments. The company currently has a limited pipeline and lacks a diverse portfolio, which could hinder its long-term growth potential. Additionally, its financials show a steady decrease in net income and an increase in operating expenses, raising concerns about its ability to sustain its operations in the future.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares